Bria-IMT + Retifanlimab vs Physician's Choice in Advanced Metastatic Breast Cancer
Market
Trade
Will this trial meet its primary endpoint?
Paper Trading
Create account to trade- Primary Completion
- 12/1/27
- Study Completion
- 6/1/28
- Sponsor
- BriaCell Therapeutics Corporation
- Ticker
- Unavailable
- Type
- Trial Status
- Recruiting
- Trial Size
- 404
- NCT
- NCT06072612
- Trial Description
- Randomized, open-label Phase 3 study in advanced metastatic or locally recurrent breast cancer evaluating the Bria-IMT regimen plus retifanlimab against physician's choice chemotherapy in patients with no approved alternative therapies available. The primary endpoint is overall survival, with estimated enrollment of 404 patients.